Ani Pharmaceuticals (ANIP) Equity Average (2011 - 2026)

Ani Pharmaceuticals has disclosed Equity Average across 16 years of filings, most recently posting $551.5 million for Q1 2026.

• Equity Average for Q1 2026 came in at $551.5 million, up 105.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $551.5 million (up 105.63% YoY), and the FY2025 annual result was $273.0 million, up 10114.52% from the prior year.
• Equity Average came in at $551.5 million for Q1 2026 at Ani Pharmaceuticals, up from $523.3 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $551.5 million in Q1 2026 to a low of -$48.7 million in Q3 2022.
• The 5-year median for Equity Average is $207.5 million (2023), against an average of $204.4 million.
• Across the five-year window, Equity Average slumped 125.4% in 2022 and soared 26084800.0% in 2024, its largest moves.
• Ani Pharmaceuticals' Equity Average stood at $155.6 million in 2022, then sank by 100.0% to $2000.0 in 2023, then surged by 12905975.0% to $258.1 million in 2024, then jumped by 102.72% to $523.3 million in 2025, then grew by 5.4% to $551.5 million in 2026.
• The last three Equity Average figures came in at $551.5 million (Q1 2026), $523.3 million (Q4 2025), and $214.5 million (Q3 2025), per Business Quant data.